Literature DB >> 10882227

Effect of rebamipide on prostaglandin EP4 receptor gene expression in rat gastric mucosa.

H Suetsugu1, S Ishihara, N Moriyama, H Kazumori, K Adachi, R Fukuda, M Watanabe, Y Kinoshita.   

Abstract

Prostaglandin E2 (PGE2) plays an important role in the regulation of gastric mucus secretion. We have previously shown that the prostaglandin EP4 receptor (EP4) gene is abundantly expressed in gastric mucus-producing cells. Furthermore, we have shown that EP4 is present in a rat normal gastric mucosal cell line (RGM1) and that PGE2 increases mucus secretion from these cells via EP4. Rebamipide, an anti-gastric ulcer agent, has been reported to promote gastric PGE2 production and mucus secretion. However, it is unclear whether rebamipide influences mucus secretion by altering expression of the EP4 gene. Therefore, we tested the effect of rebamipide on EP4 gene expression in the gastric mucosa. Seven-week-old Wistar rats received oral rebamipide (100 mg/kg) with and without water-immersion restraint stress (WRS). All rats were killed, and their gastric tissues were used to investigate the expression of mRNA for EP4 and cyclooxygenase types 1 and 2. The thickness of the gastric mucus layer was also measured. The effect of rebamipide on EP4 gene expression and PGE2 production in RGM1 cells was also investigated in vitro. Furthermore, the effect of PGE2 on cyclic adenosine monophosphate (cAMP) production by RGM1 cells with or without rebamipide was studied. Oral rebami-pide significantly increased EP4 gene expression in the gastric antrum but not in the corpus after WRS. Furthermore, it increased surface mucus thickness and suppressed ulcer formation in the gastric mucosa after WRS. In vitro, rebamipide significantly augmented EP4 gene expression in RGM1 cells, and PGE2 significantly increased the cAMP production by RGM1 cells incubated with rebamipide. Rebamipide promotes EP4 gene expression and may consequently increase the gastric mucus secretion via EP4 receptors in the rat antral mucosa.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10882227     DOI: 10.1067/mlc.2000.107303

Source DB:  PubMed          Journal:  J Lab Clin Med        ISSN: 0022-2143


  12 in total

1.  A study on the efficacy of rebamipide for patients with proton pump inhibitor-refractory non-erosive reflux disease.

Authors:  Kyoichi Adachi; Kenji Furuta; Hiroto Miwa; Tadayuki Oshima; Masaharu Miki; Yoshinori Komazawa; Katsuhiko Iwakiri; Takahisa Furuta; Tomoyuki Koike; Tomohiko Shimatani; Yoshikazu Kinoshita
Journal:  Dig Dis Sci       Date:  2012-02-26       Impact factor: 3.199

2.  Endogenous cyclo-oxygenase activity regulates mouse gastric surface pH.

Authors:  Heidi K Baumgartner; Uzay Kirbiyik; Tamer Coskun; Shaoyou Chu; Marshall H Montrose
Journal:  J Physiol       Date:  2002-11-01       Impact factor: 5.182

Review 3.  15th anniversary of rebamipide: looking ahead to the new mechanisms and new applications.

Authors:  Tetsuo Arakawa; Kazuhide Higuchi; Yasuhiro Fujiwara; Toshio Watanabe; Kazunari Tominaga; Eiji Sasaki; Nobuhide Oshitani; Toshikazu Yoshikawa; Andrzej S Tarnawski
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

4.  Rebamipide enema is effective for treatment of experimental dextran sulfate sodium induced colitis in rats.

Authors:  Takako Nakashima; Takashi Maeda; Hisashi Nagamoto; Takeshi Kumakura; Masaaki Takai; Toyoki Mori
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

5.  Rebamipide, a gastro-protective drug, inhibits indomethacin-induced apoptosis in cultured rat gastric mucosal cells: association with the inhibition of growth arrest and DNA damage-induced 45 alpha expression.

Authors:  Yuji Naito; Hirokazu Kajikawa; Katsura Mizushima; Makoto Shimozawa; Masaaki Kuroda; Kazuhiro Katada; Tomohisa Takagi; Osamu Handa; Satoshi Kokura; Hiroshi Ichikawa; Norimasa Yoshida; Hirofumi Matsui; Toshikazu Yoshikawa
Journal:  Dig Dis Sci       Date:  2005-10       Impact factor: 3.199

6.  Management of recurrence of symptoms of gastroesophageal reflux disease: synergistic effect of rebamipide with 15 mg lansoprazole.

Authors:  Norimasa Yoshida; Kazuhiro Kamada; Naoya Tomatsuri; Takahiro Suzuki; Tomohisa Takagi; Hiroshi Ichikawa; Toshikazu Yoshikawa
Journal:  Dig Dis Sci       Date:  2010-03-03       Impact factor: 3.199

7.  Effects of prostaglandins on spontaneous apoptosis in gastric mucosal cells.

Authors:  Shinji Tsutsumi; Reiko Haruna; Wataru Tomisato; Tatsunori Takano; Tatsuya Hoshino; Tomofusa Tsuchiya; Tohru Mizushima
Journal:  Dig Dis Sci       Date:  2002-01       Impact factor: 3.199

8.  Rebampide enema therapy as a treatment for patients with chronic radiation proctitis: initial treatment or when other methods of conservative management have failed.

Authors:  Tae Oh Kim; Geun Am Song; Sun Mi Lee; Gwang Ha Kim; Jeong Heo; Dae Hwan Kang; Mong Cho
Journal:  Int J Colorectal Dis       Date:  2008-03-08       Impact factor: 2.571

9.  Treating ocular surface disease: new agents in development.

Authors:  Ahmad M Fahmy; David R Hardten
Journal:  Clin Ophthalmol       Date:  2011-04-14

10.  Rebamipide suppresses TLR-TBK1 signaling pathway resulting in regulating IRF3/7 and IFN-α/β reduction.

Authors:  Naotaka Ogasawara; Makoto Sasaki; Yukimi Itoh; Kentaro Tokudome; Yoshihiro Kondo; Yoshitsugi Ito; Satoshi Tanida; Takeshi Kamiya; Hiromi Kataoka; Takashi Joh; Kunio Kasugai
Journal:  J Clin Biochem Nutr       Date:  2011-02-26       Impact factor: 3.114

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.